Abstract：Objective To investigate the efficacy and safety of Dapagliflozin combined with Metformin in the patients with type 2 diabetes mellitus and provide evidence of clinical trantment.Methods A total of 105 patients newly diagnosed with T2DM in DongGuan Tungwah Hospital from May 2019 to August 2020 were selected as the research objects.According to the simple randomized principle,the patients were divided into the Dapagliflozin group(27 patients),Saxagliptin group(26 patients),Acarbose group(27 patients)and Glimepiride group(25 patients).All groups were simultaneously treated with Metformin for 12 weeks.Body mass index(BMI),systolic blood pressure(SBP),diastolic blood pressure(DBP),fasting blood glucose(FPG),2 hours postprandial blood glucose(PBG),glycated hemoglobin(HbA1c),islet β-cell function index(HOMA-β),serum uric acid(SUA),serum creatinine(SCr),total cholesterol(TC)and triacylglycerin in 4 groups were compared(TG),alanine aminotransferase(ALT),alanine aminotransferase(AST)levels and adverse reactions were cimpared among the four groups.Results Before treatment,there were no significant differences in BMI,SBP,DBP,FPG,PBG,HbA1c,SUA,SCr,TC,TG,ALT and AST among the four groups(P＞0.05).After treatment,the levels of FPG,PBG,HbA1c and HOMA-β in the four groups were lower than those before treatment,the differences were statistically significant(P＜0.05).After treatment,The BMI,SBP,TC,TG and SUA of Dagaglipin group were lower than those before treatment,the differences were statistically significant(P＜0.05).After treatment,FPG,HbA1c,HOMA-β,BMI,SBP,TG and SUA in Dagagliptin group were lower than those in Saxagliptin group,Acarbose group and Glimepirea group(P＜0.05).The total incidence of adverse events in the Dagagligin group was 3.7%,lower than that in the Acarbose group(29.6%),and the difference was statistically significant(P＜0.05).Conclusion Dapagliflozin plus Metformin have better treatment results in patients with T2DM mellitus.It can effectively reduce blood glucose fluctuations,and improve many metabolic indexes.There is no obvious gastrointestinal reaction and high safety,which is worthy of promotion.
田睿;贲吕红. 达格列净联合二甲双胍治疗2型糖尿病患者的效果和安全性[J]. 中国当代医药, 2022, 29(10): 107-110.
TIAN Rui; BEN Lyuhong. Clinical efficacy of Dapagliflozin combined with Metformin in the patients with type 2 diabetes mellitus. 中国当代医药, 2022, 29(10): 107-110.
Li Y，Teng D，Shi X，et al.Prevalence of diabetes recorded in mainland china using 2018 diagnostic criteria from the American Diabetes Association：national cross sectional study[J].BMJ，2020，28：369.
Perry RJ，Shulman GI.Sodium-glucose cotransporter-2 inhibitors：understanding the mechanisms for therapeutic promise and persisting risks[J].J Biol Chem，2020，95（42）：14 379-14 390.
[8]
American Diabetes Association.9.Pharmacologic approaches to glycemic treatment：standards of medical care indiabetes-2021[J].Diabetes Care，2020，43（Suppl 1）：S98-S110.
Marx N，Davies MJ，Grant PJ，et al.Guideline recommendations and the positioning of newer drugs in type 2 diabetes care[J].Lancet Diabetes Endocrinol，2019，9（1）：46-52.
European Society of Cardiology.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J，2021，42（36）：3599-3726.
[20]
American Diabetes Association.Standards of Medical Care in Diabetes-2021[J].Diabetes Care，2021，44（Suppl 1）：S1-S2.
京公网安备 11010502046607号